The Use of Risperidone to Treat First-Episode Schizophrenia. Preliminarily examination about effects on five dimensions of PANSS.
|
Accession number;01A0282750
|
| Title;The Use of Risperidone to Treat First-Episode Schizophrenia. Preliminarily examination about effects on five dimensions of PANSS. |
| Author;
TONAI EITA
(Fukuoka Univ., Fac. of Med.)
ISHII HISANORI
(Fukuoka Univ., Fac. of Med.)
KOHARA KIMIO
(Fukuokakenseishin'iryose Dazaifubyoin)
NISHIMURA RYOJI
(Fukuoka Univ., Fac. of Med.)
|
Journal Title;Kyushu Neuropsychiatry
|
Journal Code:Z0180B
|
ISSN:0023-6144
|
|
VOL.46;NO.3/4;PAGE.182-188(2000)
|
| Figure&Table&Reference;FIG.2, TBL.4, REF.21 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;The effectiveness of risperidone in the treatment of first-episode schizophrenia has yet to be established. Previous studies have supported the use of risperidone for the treatment of chronic schizophrenia. This study investigated the effectiveness of risperidone in reducing the clinical symptoms in the treatment of first-episode schizophrenia. Six first-episode schizophrenic inpatients were selected to be administered open dose Risperidone. The PANSS (Positive and Negative Syndrome Scale), which was performed at the time of admission and discharge, was used to evaluate the effectiveness of this drug in reducing symptoms. During hospitalization, the total PANSS score for all 6 subjects improved by at least 35%. We used a factor analysis of PANNS to determine 5 dimensions for the symptoms (evaluation positive symptoms, negative symptoms, disorganized thought, hostility/excitement, and anxiety/depression). The Patients administered risperidone showed a 50% reduction in the scores for positive symptoms, disorganized thought, and hostility/excitement, which are considered to be the characteristic symptoms of acute phase, and the scores of the other two dimensions also showed some improvement (13.9% for negative symptoms, 33.9% for anxiety/depression). These findings suggest that risperidone may therefore be an effective first-choice medication for first-episode schizophrenia. (author abst.) |
|
|
|
Related Articles;
|
|
